title: Galanin-induced decreases in nucleus accumbens/striatum excitatory postsynaptic potentials and morphine conditioned place preference require both galanin receptor 1 and galanin receptor 2.
abstract: The neuropeptide galanin has been shown to alter the rewarding properties of morphine. To identify potential cellular mechanisms that might be involved in the ability of galanin to modulate opiate reward, we measured excitatory postsynaptic potentials (EPSPs), using both field and whole-cell recordings from striatal brain slices extracted from wild-type mice and mice lacking specific galanin receptor (GalR) subtypes. We found that galanin decreased the amplitude of EPSPs in both the dorsal striatum and nucleus accumbens. We then performed recordings in slices from knockout mice lacking either the GalR1 or GalR2 gene, and found that the ability of galanin to decrease EPSP amplitude was absent from both mouse lines, suggesting that both receptor subtypes are required for this effect. In order to determine whether behavioral responses to opiates were dependent on the same receptor subtypes, we tested GalR1 and GalR2 knockout mice for morphine conditioned place preference (CPP). Morphine CPP was significantly attenuated in both GalR1 and GalR2 knockout mice. These data suggest that mesolimbic excitatory signaling is significantly modulated by galanin in a GalR1-dependent and GalR2-dependent manner, and that morphine CPP is dependent on the same receptor subtypes.
authors: Division of Molecular Psychiatry, Department of Psychiatry, Yale University School of Medicine, 34 Park Street - 3rd floor research, New Haven, CT 06508, USA.
authors: Emily B
authors: EB
authors: Einstein
authors: Yukiko
authors: Y
authors: Asaka
authors: Mark F
authors: MF
authors: Yeckel
authors: Michael J
authors: MJ
authors: Higley
authors: Marina R
authors: MR
authors: Picciotto
mesh_terms: D000818:Animals; D003214:Conditioning, Classical; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D019706:Excitatory Postsynaptic Potentials; D019004:Galanin / Q000494:pharmacology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009020:Morphine / Q000494:pharmacology; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D044091:Receptor, Galanin, Type 1 / Q000235:genetics / Q000378:metabolism*; D044092:Receptor, Galanin, Type 2 / Q000235:genetics / Q000378:metabolism*
chemical_list: D044091:Receptor, Galanin, Type 1; D044092:Receptor, Galanin, Type 2; D009020:Morphine; D019004:Galanin
references: J Cereb Blood Flow Metab. 1997 Jul;17(7):713-31
references: 9270488
references: Regul Pept. 2005 Jan 15;124(1-3):37-43
references: 15544839
references: Mol Cell Biol. 2004 Apr;24(7):2978-85
references: 15024085
references: J Neurophysiol. 1993 Apr;69(4):1236-44
references: 8388042
references: Annu Rev Neurosci. 2005;28:403-50
references: 16022602
references: Neuroscience. 2006 Sep 1;141(3):1503-15
references: 16806720
references: Brain Res. 2010 Feb 16;1314:206-18
references: 19699187
references: Psychopharmacology (Berl). 2009 May;204(1):95-102
references: 19099295
references: Mol Pain. 2011 Apr 16;7:26
references: 21496293
references: Biol Psychiatry. 2012 Jun 15;71(12):1061-7
references: 22196983
references: Ann N Y Acad Sci. 1999 Jun 29;877:157-75
references: 10415649
references: Neuropeptides. 2005 Jun;39(3):269-75
references: 15944021
references: J Biol Chem. 1997 Sep 26;272(39):24612-6
references: 9305929
references: Neuropharmacology. 2009;56 Suppl 1:122-32
references: 18675281
references: Brain Res. 1999 Mar 20;822(1-2):200-9
references: 10082897
references: J Neurochem. 1998 Dec;71(6):2239-51
references: 9832121
references: Brain Res. 1999 Jun 12;831(1-2):33-42
references: 10411981
references: PLoS One. 2011 Apr 22;6(4):e19155
references: 21544206
references: Annu Rev Med. 2004;55:113-32
references: 14746512
references: J Physiol. 2003 Aug 1;550(Pt 3):911-9
references: 12824447
references: J Biol Chem. 1998 Sep 4;273(36):23321-6
references: 9722565
references: Drug Alcohol Depend. 2006 Feb 1;81(2):103-7
references: 16023304
references: Trends Pharmacol Sci. 2000 Mar;21(3):109-17
references: 10689365
references: Neurosci Lett. 1990 Feb 5;109(1-2):217-21
references: 1690366
references: Neuroscience. 1995 Feb;64(4):861-74
references: 7538638
references: Neuroscience. 1984 Mar;11(3):617-25
references: 6717805
references: Crit Rev Neurobiol. 1998;12(4):267-303
references: 10348612
references: J Neurosci. 2011 May 18;31(20):7412-23
references: 21593325
references: JAMA. 2007 Jan 17;297(3):249-51
references: 17227967
references: Behav Neurosci. 2010 Dec;124(6):828-38
references: 21038934
references: Neuropsychopharmacology. 2010 Jan;35(1):217-38
references: 19710631
references: Alcohol Clin Exp Res. 2010 Jan;34(1):72-80
references: 19860804
references: Proc Natl Acad Sci U S A. 2002 May 14;99(10):7136-41
references: 12011470
references: J Neural Transm Gen Sect. 1993;93(1):11-25
references: 8373553
references: Alcohol. 2009 Dec;43(8):571-80
references: 20004335
references: J Neurosci. 1996 May 1;16(9):3112-22
references: 8622141
references: Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12671-6
references: 9770544
references: J Neural Transm Gen Sect. 1995;102(3):229-35
references: 8788071
references: Pharmacol Biochem Behav. 2011 Mar;98(1):87-93
references: 21172385
references: Exp Neurol. 1994 May;127(1):23-36
references: 8200435
references: Brain Res Mol Brain Res. 2002 Nov 15;107(2):195-200
references: 12487125
references: J Neurochem. 2006 Nov;99(3):1000-10
references: 17076662
references: Neuroendocrinology. 2003 Jun;77(6):354-66
references: 12845222
references: J Comp Neurol. 1999 Jul 5;409(3):469-81
references: 10379831
references: Neuropeptides. 2005 Jun;39(3):299-304
references: 15944026
references: Brain Res Mol Brain Res. 1995 Dec 28;34(2):179-89
references: 8750821
references: Brain Res. 2000 Jan 10;852(2):485-7
references: 10678779
references: Ann N Y Acad Sci. 1992 Jun 28;654:171-91
references: 1632582
references: Neuropeptides. 2010 Oct;44(5):445-51
references: 20580982
references: Brain Res. 2001 Nov 16;919(1):169-74
references: 11689176
references: J Pharmacol Exp Ther. 2004 Feb;308(2):574-82
references: 14610237
references: Pharmacol Ther. 2007 Aug;115(2):177-207
references: 17604107
references: Neuropsychopharmacology. 2008 Jul;33(8):1864-73
references: 17957220
references: Am J Hypertens. 1998 Dec;11(12):1475-9
references: 9880130